CD8A and neoplasm: As TIM3 has been known to inhibit CD8+ cytotoxic activity and therefore can contribute to tumor progression (50), these studies emphasize the promise of CellPhoneDB to uncover conserved biomarkers for therapy resistance from scRNA-seq.